Sage Journals HomeSage Journals Home
loading
Phase 1 Trial of the Safety and Immunogenicity of PENNVAX ® -G DNA Prime Administered by Biojector ® 2000 or CELLECTRA ® EP Device with MVA-CMDR Boost